Efficacy of hemostatic powders in upper gastrointestinal bleeding: A systematic review and meta-analysis

2019 ◽  
Vol 51 (12) ◽  
pp. 1633-1640 ◽  
Author(s):  
Antonio Facciorusso ◽  
Marcelo Straus Takahashi ◽  
Ceren Eyileten Postula ◽  
Vincenzo Rosario Buccino ◽  
Nicola Muscatiello
Keyword(s):  
Systematic Review ◽  
Gastrointestinal Bleeding ◽  
Upper Gastrointestinal Bleeding ◽  
Meta Analysis ◽  
Upper Gastrointestinal

scholarly journals Use of hemostatic powder in treatment of upper gastrointestinal bleeding: a systematic review and meta-analysis

2019 ◽  
Vol 07 (12) ◽  
pp. E1704-E1713 ◽  
Author(s):  
Daniel Tavares de Rezende ◽  
Vitor Ottoboni Brunaldi ◽  
Wanderley Marques Bernardo ◽  
Igor Braga Ribeiro ◽  
Raquel Cristina Lins Mota ◽  
...  
Keyword(s):  
Systematic Review ◽  
Gastrointestinal Bleeding ◽  
Latin American ◽  
Upper Gastrointestinal Bleeding ◽  
Rescue Therapy ◽  
Meta Analysis ◽  
Secondary Outcome ◽  
Primary Hemostasis ◽  
Hemostatic Powder ◽  
Upper Gastrointestinal

Abstract Background and study aims TC-325 is a novel mineral hemostatic powder that creates a mechanical barrier by absorbing blood components and promoting clotting. Recently approved for use in humans, it has shown promise for treatment of upper gastrointestinal bleeding (UGIB). However, because there have been no large studies of TC-325, its true efficacy and safety profile remain unknown. We performed a systematic review and meta-analysis to determine the safety and efficacy of TC-325 in treating UGIB, based on rates of initial hemostasis, rebleeding, and adverse events (AEs). Methods We searched the MEDLINE/PubMed, EMBASE, CENTRAL, Latin-American and Caribbean Health Sciences Literature databases, as well as the gray literature, to identify articles describing use of TC-325 up to October 2018. Primary outcomes were initial hemostasis and rebleeding. AEs were described as a secondary outcome. Risk of bias was assessed with international scores. Results We identified 2077 records after removal of duplicates. We included 50 studies, involving a collective total of 1445 patients, in the quantitative synthesis. Primary hemostasis and rebleeding rates were 90.7 % and 26.1 %, respectively. Subgroup analyses showed similar results. Only eight AEs were reported. Conclusions TC-325 appears to be a safe, effective treatment for UGIB. The overall rate of initial hemostasis after TC-325 use is high, regardless of etiology of bleeding or whether TC-325 is used as a primary or rescue therapy. Although it is also associated with high rebleeding rates, rates of AEs and equipment failure after TC-325 use are extremely low.

scholarly journals Systematic review with meta-analysis: the efficacy of tranexamic acid in upper gastrointestinal bleeding

2020 ◽  
Vol 51 (11) ◽  
pp. 1004-1013 ◽  
Author(s):  
Erica Twum-Barimah ◽  
Ibtihal Abdelgadir ◽  
Morris Gordon ◽  
Anthony K. Akobeng
Keyword(s):  
Systematic Review ◽  
Gastrointestinal Bleeding ◽  
Tranexamic Acid ◽  
Upper Gastrointestinal Bleeding ◽  
Meta Analysis ◽  
Upper Gastrointestinal

Tu1094 THE USE OF HEMOSTATIC POWDER IN UPPER GASTROINTESTINAL BLEEDING: A SYSTEMATIC REVIEW AND META-ANALYSIS

2019 ◽  
Vol 89 (6) ◽  
pp. AB553
Author(s):  
Daniel T. Rezende ◽  
Wanderlei M. Bernardo ◽  
Vitor O. Brunaldi ◽  
Igor B. Ribeiro ◽  
Sérgio E. Matuguma ◽  
...  
Keyword(s):  
Systematic Review ◽  
Gastrointestinal Bleeding ◽  
Upper Gastrointestinal Bleeding ◽  
Meta Analysis ◽  
Hemostatic Powder ◽  
Upper Gastrointestinal
Sign in / Sign up

Export Citation Format

Share Document